Surgical infections with Enterococcus: Outcome in patients treated with ertapenem versus Piperacillin-Tazobactam

Surgical Infections

Volumn 3, Issue 4, 2002, Pages 337-349

  Teppler, Hedy ^a   McCarroll, Kathleen ^a   Gesser, Richard M ^a   Woods, Gail L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIFUNGAL AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; VANCOMYCIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SENSITIVITY; ENTEROCOCCUS; FEMALE; HUMAN; IN VITRO STUDY; LOGISTIC REGRESSION ANALYSIS; MALE; PELVIC INFLAMMATORY DISEASE; POSTOPERATIVE INFECTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SURGICAL INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036928680     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629602762539553     Document Type: Article

References (22)

1. Evans AC, Chinn AL. The enterococci: With special reference to their association with human disease. J Bacteriol 1947;54:495-512.
2. Rantz LA, Kirby WMM. Enterococcic infections: an evaluation of the importance of fecal streptococcal and related organisms in the causation of human disease. Arch Intern Med 1943;17:516-528.
3. Jett BD, Huycke MM, Gilmore M. Virulence of enterococci. Clin Microbiol Rev 1994;7:462-478.
4. Garrison RN, Fry DE, Berberich S, et al. Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg 1982;196:43-47.
5. Dougherty SH. Role of Enterococcus in intraabdominal sepsis. Am J Surg 1984;148:308-312.
6. Nichols RL, Muzik AC. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992;15:72-76.
7. Barie PS. Enterococcus in perspective. Surg Infect 2000; 1:91-93.
8. Onderdonk AB, Bartlett JG, Louie TJ, et al. Microbial synergy in experimental intra-abdominal abscesses. Infect Immun 1976;13:22-26.
9. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-1302.
10. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992;127:83-89.
11. Barie PS, Christou NV, Dellinger EP, et al. Pathogenicity of the Enterococcus in surgical infections. Ann Surg 1990;212:155-159.
12. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995;118:716-723.
13. Graham D, Lucasti C, Malafaia O, et al. Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis (in press).
14. Roy S, Higareda I, Angel-Muller E, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infectious Diseases in Obstetrics and Gynecology (in press).
15. Solomkin JS, Yellin AE, Rotstein OD, et al. Results of a double-blind, randomized, comparative trial of ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery (in press).
16. Beam TR Jr, Gilbert DN, Kunin DM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992;15(Suppl 1):S5-32.
17. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. NCCLS document M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
18. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved Standard, M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
19. Tan JS, Wishnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993;37:1580-1586.
20. Siami G, Christou N, Eiseman I, et al. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001;45:525-531.
21. Rohrborn A, Wacha H, Schoffel U, et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect 2000; 1:95-107.
22. Horvitz RA, von Graevenitz A. A clinical study of the role of enterococci as sole agents of wound and tissue infection. Yale J Biol Med 1977;50:391-395.